Yazar "Baran, Fatma Bengisu" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Demodex parasite density in patients with melasma: a case-control study
    (Taylor & Francis Ltd, 2026) Baran, Fatma Bengisu; Altunisik, Nihal; Turkmen, Dursun; Kanat, Zekiye; Sener, Serpil
    Background: Although multiple factors contribute to the development of melasma, there are reports suggesting a potential role of Demodex parasites in hyperpigmentation. This study aimed to compare the density and prevalence of Demodex infestation between patients with melasma and healthy controls. Methods: This case-control study included 35 melasma patients and 35 healthy volunteers. Standard superficial skin biopsies using cyanoacrylate adhesive were taken from the malar regions. Samples were examined via light microscopy, with a density of >= 5 Demodex/cm(2) defined as positive. Results: No statistically significant difference was found between the melasma and control groups in terms of Demodex mite density or positivity rates. Correlation analysis revealed no significant relationship between mMASI scores and Demodex mite density. As a secondary finding, the mean mMASI score was significantly higher in male participants compared to female participants. Conclusion: In this case-control study, we found no statistically significant association between Demodex parasite density and melasma in our study population. While our findings do not support an association in this sample, future large-scale and multicenter studies could further explore the potential role of Demodex in skin disorders that have been suggested by other reports. The single-center design and moderate sample size should be considered when interpreting these results.
  • Küçük Resim Yok
    Öğe
    GRWD1 Drives Melanoma Growth Through NF-κB Signaling Pathway
    (Mattioli 1885, 2025) Turkmen, Dursun; Ozbey, Rafet; Ozdem, Berna; Alan, Saadet; Cetin, Ayten Kilincli; Baran, Fatma Bengisu; Dogan, Berat
    Introduction: Melanoma is an aggressive skin cancer with high metastatic potential. The oncogenic protein GRWD1 has been implicated in various cancer types, but its role in melanoma remains unclear. Objectives: To examine the effects of GRWD1 knockdown on melanoma cell proliferation, apoptosis, and migration and to evaluate its prognostic significance in melanoma patients. Methods: A combination of in vitro and clinical analyses was performed. A2058 melanoma cells were treated with GRWD1-specific siRNA, and cell proliferation, apoptosis, and migration assays were conducted. Western blotting was used to assess alterations in key oncogenic pathways. Additionally, clinical tissue samples from melanoma patients were analyzed for GRWD1 expression, and Kaplan-Meier survival analysis was performed to determine its prognostic value. Results: GRWD1 was highly expressed in melanoma cells. GRWD1 knockdown significantly reduced cell proliferation (by 63%), impaired colony formation, and induced apoptosis (cleaved caspase-3 levels increased by 17.3%). Migration capacity decreased by 70%, and NF-kappa B pathway activity was suppressed, leading to reduced expression of Bcl-2, Src, and MDM2, while stabilizing p53. TCGA-based analyses revealed that high GRWD1 expression was significantly associated with shorter survival in metastatic melanoma cases (P=0.00029) but showed no correlation with melanoma subtypes. However, in immunohistochemical analysis of clinical samples, no statistically significant correlation was found between GRWD1 staining intensity and survival. Conclusions: GRWD1 plays a crucial role in melanoma progression by enhancing NF-kappa B activity, promoting proliferation, and suppressing apoptosis. While high GRWD1 expression is associated with poor prognosis in public datasets, further clinical validation with larger patient cohorts is needed to confirm its utility as a prognostic biomarker and therapeutic target.